Reviewing Petros Pharmaceuticals (NASDAQ:PTPI) & Vincerx Pharma (NASDAQ:VINC)

Volatility and Risk

Vincerx Pharma has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Insider & Institutional Ownership

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vincerx Pharma and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Valuation and Earnings

This table compares Vincerx Pharma and Petros Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00
Petros Pharmaceuticals	$5.11 million	0.08	-$8.16 million	($39.69)	0.00

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 5 of the 9 factors compared between the two stocks.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.